Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD

Gut

Volumn 67, Issue 10, 2018, Pages

  Jiao, Na ^a   Baker, Susan S ^b,c   Chapa Rodriguez, Adrian ^b   Liu, Wensheng ^b   Nugent, Colleen A ^b   Tsompana, Maria ^b   Mastrandrea, Lucy ^b   Buck, Michael J ^b,c   Baker, Robert D ^b   Genco, Robert J ^b,c   Zhu, Ruixin ^a   Zhu, Lixin ^b,c  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BILE ACID; BILE SALT EXPORT PUMP; CHENODEOXYCHOLIC ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLIC ACID; DEOXYCHOLIC ACID; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCINE; HETERODIMER; MESSENGER RNA; SODIUM BILE ACID COTRANSPORTER; TAURINE; URSODEOXYCHOLIC ACID; CELL RECEPTOR; CYP7A1 PROTEIN, HUMAN; FARNESOID X-ACTIVATED RECEPTOR; FIBROBLAST GROWTH FACTOR;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; INTESTINE FLORA; LIPID DIET; MALE; NEWBORN; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PHYSIOLOGY;

ANIMALS; BILE ACIDS AND SALTS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; DIET, HIGH-FAT; FEMALE; FIBROBLAST GROWTH FACTORS; GASTROINTESTINAL MICROBIOME; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 85048040313     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2017-314307     Document Type: Article

References (49)

1. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013;162:496-500.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
3. Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 2016;64:1577-86.
4. Arab JP, Karpen SJ, Dawson PA, et al. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 2017;65.
5. Rao A, Kosters A, Mells JE, et al. Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice. Sci Transl Med 2016;8:357ra122.
6. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408-18.
7. Pineda Torra I, Claudel T, Duval C, et al. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003;17:259-72.
8. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005;2:217-25.
9. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009;10:167-77.
10. Baggio LL, Drucker DJ. Biology of incretins: glp-1 and GIP. Gastroenterology 2007;132:2131-57.
11. Alarcon C, Wicksteed B, Rhodes CJ. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia 2006;49:2920-9.
12. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal Bacteria. J Lipid Res 2006;47:241-59.
13. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-8.
14. Yu J, Lo JL, Huang L, et al. Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem 2002;277:31441-7.
15. Sayin SI, Wahlström A, Felin J, et al. Gut Microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 2013;17:225-35.
16. Duboc H, Taché Y, Hofmann AF. The bile acid TGR5 membrane receptor: from basic research to clinical application. Dig Liver Dis 2014;46:302-12.
17. Mouzaki M, Wang AY, Bandsma R, et al. Bile acids and Dysbiosis in Non-Alcoholic Fatty liver disease. PLoS One 2016;11:e0151829.
18. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
19. Feng Q, Baker SS, Liu W, et al. Increased apolipoprotein A5 expression in human and rat non-alcoholic fatty livers. Pathology 2015;47:341-8.
20. Liu W, Baker SS, Baker RD, et al. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS One 2011;6:e24363.
21. Baker SS, Baker RD, Liu W, et al. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS One 2010;5:e9570.
22. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013;57:601-9.
23. Fadrosh DW, Ma B, Gajer P, et al. An improved dual-indexing approach for multiplexed 16S rRNA gene sequencing on the Illumina MiSeq platform. Microbiome 2014;2:6.
24. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol 2013;31:814-21.
25. Moya D, Baker SS, Liu W, et al. Novel pathway for iron deficiency in pediatric nonalcoholic steatohepatitis. Clin Nutr 2015;34:549-56.
26. Yuan J, Baker SS, Liu W, et al. Endotoxemia unrequired in the pathogenesis of pediatric nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2014;29:1292-8.
27. Desai S, Baker SS, Liu W, et al. Paraoxonase 1 and oxidative stress in paediatric nonalcoholic steatohepatitis. Liver Int 2014;34:110-7.
28. Zhu L, Baker SS, Liu W, et al. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism 2011;60:1001-11.
29. Lin BC, Wang M, Blackmore C, et al. Liver-specific activities of FGF19 require klotho beta. J Biol Chem 2007;282:27277-84.
30. Gutierrez A, Ratliff EP, Andres AM, et al. Bile acids decrease hepatic paraoxonase 1 expression and plasma high-density lipoprotein levels via FXR-mediated signaling of FGFR4. Arterioscler Thromb Vasc Biol 2006;26:301-6.
31. Shih DM, Kast-Woelbern HR, Wong J, et al. A role for FXR and human FGF-19 in the repression of paraoxonase-1 gene expression by bile acids. J Lipid Res 2006;47:384-92.
32. Reddy BS, Mangat S, Sheinfil A, et al. Effect of type and amount of dietary fat and 1,2-dimethylhydrazine on biliary bile acids, fecal bile acids, and neutral sterols in rats. Cancer Res 1977;37:2132-7.
33. Reddy BS. Diet and excretion of bile acids. Cancer Res 1981;41:3766-8.
34. Cariou B, Chetiveaux M, Zair Y, et al. Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. Nutr Metab 2011;8:48.
35. Haeusler RA, Astiarraga B, Camastra S, et al. Human insulin resistance is associated with increased plasma levels of 12-hydroxylated bile acids. Diabetes 2013;62:4184-91.
36. Brufau G, Stellaard F, Prado K, et al. Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism. Hepatology 2010;52:1455-64.
37. Ferslew BC, Xie G, Johnston CK, et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2015;60:3318-28.
38. Min HK, Kapoor A, Fuchs M, et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012;15:665-74.
39. Bechmann LP, Kocabayoglu P, Sowa JP, et al. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013;57:1394-406.
40. Jahnel J, Zohrer E, Alisi A, et al. Serum bile acid levels in Children with Nonalcoholic Fatty liver disease. J Pediatr Gastroenterol Nutr 2015;61:85-90.
41. Einarsson K, Nilsell K, Leijd B, et al. Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med 1985;313:277-82.
42. Bray GA, Popkin BM. Dietary fat intake does affect obesity!. Am J Clin Nutr 1998;68:1157-73.
43. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147-91.
44. Plass JR, Mol O, Heegsma J, et al. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 2002;35:589-96.
45. Jung D, Inagaki T, Gerard RD, et al. FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. J Lipid Res 2007;48:2693-700.
46. Degirolamo C, Rainaldi S, Bovenga F, et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 Axis in mice. Cell Rep 2014;7:12-18.
47. Sinal CJ, Tohkin M, Miyata M, et al. Targeted disruption of the nuclear receptor FXR/ BAR impairs bile acid and lipid homeostasis. Cell 2000;102:731-44.
48. Lambert G, Amar MJ, Guo G, et al. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003;278:2563-70.
49. Zhang Y, Lee FY, Barrera G, et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 2006;103:1006-11.